Pad Chivukula - Jun 1, 2023 Form 4 Insider Report for Arcturus Therapeutics Holdings Inc. (ARCT)

Role
Chief Scientific Officer & COO
Signature
/s/ Ilan Katz, attorney-in-fact
Stock symbol
ARCT
Transactions as of
Jun 1, 2023
Transactions value $
-$135,800
Form type
4
Date filed
6/5/2023, 04:07 PM
Previous filing
May 12, 2023
Next filing
Jul 7, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARCT Common Stock Sale -$136K -5K -0.9% $27.16 549K Jun 1, 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2 Reflects the weighted average price of 5,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on June 1, 2023, with sale prices ranging from $26.87 to $27.54 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.